ABSTRACT Background: To identify associations between polyphenol intake and health and disease outcomes in cohort studies, it is important to identify biomarkers of intake for the various compounds commonly consumed as part of the diet. Objective: The objective of this systematic review was to assess the usefulness of polyphenol metabolites excreted in urine as biomarkers of polyphenol intake in humans. Design: The method included a structured search strategy for polyphenol intervention studies on Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases; formal inclusion and exclusion criteria; data extraction into an Access database; validity assessment; and meta-analysis. Results: One hundred sixty-two controlled intervention studies with polyphenols were included, and mean recovery yield and correlations with the dose ingested were determined for 40 polyphenols. Polyphenols such as daidzein, genistein, glycitein, enterolactone, and hydroxytyrosol showed both a high recovery yield (12-37%) and a high correlation with the dose (Pearson's correlation coefficients: 0.67-0.87), which showed good sensitivity and robustness as biomarkers of intake throughout the different studies. Weaker recovery for anthocyanins (0.06-0.2%) and weaker correlations with dose [Pearson's correlation coefficients: 0.21-0.52 for hesperidin, naringenin, (2)-epicatechin, (2)-epigallocatechin, quercetin, and 3 microbial metabolites of isoflavones (dihydrodaidzein, equol, and O-desmethylangolensin)] suggest that they are currently less suitable as biomarkers of intake. Conclusions: These data confirm the value of certain urinary polyphenols as biomarkers of intake. A validation in populations is now needed to evaluate their specificity, sensitivity, and responsiveness to dose under free-living conditions. Am J Clin Nutr 2010; 92:801-9.
INTRODUCTION
Polyphenols are secondary plant metabolites abundant in a large variety of foods, such as fruit, vegetables, pulses, cereals, and cocoa/chocolate and in beverages, such as coffee, tea, and wine. More than 1 g of polyphenols per day is commonly ingested with the diet (1, 2) . Experimental and epidemiologic data suggest that polyphenols contribute to the prevention of some chronic diseases, such as cardiovascular diseases, diabetes, cancer, neurodegenerative diseases, and osteoporosis (3) . Their chemical structures are highly diverse. More than 500 dietary polyphenols belonging to the flavonoid, phenolic acid, stilbene, and lignan classes have been described (4) . They differ by their hydroxylation pattern, glycosylation, esterification, and, for proanthocyanidins, by their degree of polymerization. This molecular diversity has a major influence on their bioavailability and biological effects (5, 6) and must be considered when evaluating their effects on health.
Many associations between intake and a reduction in disease risk have been observed for various polyphenols in cohort studies (7) (8) (9) (10) . Polyphenol intake is most often calculated from dietary recalls, food-frequency questionnaires, and databases on the polyphenol content of foods. Tools have improved significantly over the past few years, particularly the development of databases on the content of polyphenols in foods (11) (12) (13) . However, this approach suffers from important biases due to recall errors, misreporting or difficulties in assessing portion sizes, the wide variability in the polyphenol content of a given food, and insufficient composition data for particular foods. Such biases introduce some imprecision in the measurement of intake or exposure to nutrients which substantially attenuates associations with diseases as measured in epidemiologic studies (14) . Biomarkers are objective measures, because they do not depend on dietary-assessment methods. They significantly limit biases and errors associated with dietary assessment and inaccuracies in food-composition data (15, 16) . They may allow better estimation of the magnitude of associations between intake or exposure and diseases, which could remain unnoticed even when classic methods of dietary assessment are used. In addition, biomarkers may better reflect tissue exposure to polyphenols more directly linked to their health effects than intake, because of a large interindividual variability in absorption and metabolism (17) . Finally, biomarkers may also be very useful in cohort studies when dietary intake has not been measured, when important dietary sources of polyphenols are not included in dietary records, or when some important information is lacking (ie, a distinction between the intake of green or black tea or different modes of coffee brewing).
The value and limitation of using biomarkers as a measure of polyphenol intake were previously discussed in 2 excellent reviews (18, 19) . However no attempt has yet been made to evaluate in a more systematic way the value of polyphenol metabolites in urine as biomarkers of polyphenol intake by pooling the data of individual polyphenol intervention studies. This article describes for the first time the systematic collection and analysis of data from polyphenol intervention studies to characterize the links between intake and excretion in urine. Urine was selected because of the short half-life of polyphenols in plasma and the stronger expected dependence of polyphenol concentrations on sampling time (20) . The value as biomarkers of intake or exposure of the various metabolites identified in urine is evaluated on the basis of their specificity, sensitivity, and responsiveness to the dose. Suggestions are made for the choice of most promising markers and for their validation.
METHODS
The methodology was adapted from the standard methodology developed within the framework of EURRECA to assess biomarkers of micronutrient status (21) . Intervention studies with polyphenols or polyphenol-rich foods in which polyphenols and their metabolites were quantified in urine were collected and evaluated. Data from studies fitting the inclusion criteria were pooled to assess recovery rates and the relation with the dose ingested and variability.
Study selection
The inclusion criteria for the study were as follows. The study needed to 1) be conducted in adult healthy humans; 2) be a supplementation study of polyphenols, in the form of oral supplements, fortified foods or through normal food sources, including randomized controlled trials (2 arms with or without intake of a polyphenol source and measurement of polyphenols and their metabolites at the end of the intervention period) and before-after studies (one arm and measurement of polyphenols and their metabolites before and after intake); 3) quantify polyphenol metabolites in urine; 4) provide quantitative estimates of the intake of individual polyphenols; 5) have measured urinary excretion of polyphenol metabolites over a 24-h period; 6) have included control subjects, measured baseline values, or included a washout period before the beginning of the study; 7) be published in English; and 8) have data presented in a usable format.
Search strategy
A systematic search of the scientific literature up to February 2008 was carried out through the Cochrane Library (from 1800; www.thecochranelibrary.com), MEDLINE (from 1950; www. ovid.com), and EMBASE (from 1980; www.ovid.com). The electronic search terms and search strategies in the 3 databases are summarized in Table 1 . Two independent electronic searches were run in MEDLINE and in Cochrane/EMBASE. All data were then compiled and entered into an Endnote X library (Thomson Reuters, New York, NY).
Data collection
Titles and abstracts were screened for inclusion and duplicates were removed. Full-text articles were obtained for potentially suitable articles and for those where suitability was unclear from the screening stage. The full text of all articles collected was screened for inclusion, and data for each included study were extracted into a Microsoft Access (Microsoft Corp, Redmond, WA) database. Time constraints only allowed the participation of a single reviewer to extract all of the data; however, all authors reviewed the collated data outputs before conducting the statistical analyses.
Data extracted from each article included bibliographic data, study design, location of study, study aim, intervention description (ingested dose, form, duration, and food source), analytic methodology, amounts of the polyphenol of interest ingested and excreted, characteristics of population group (age, sex, body weight, baseline status, and subpopulation details), sample size, mean measure of the polyphenol biomarker and variability for the intervention according to the database designed for data extraction on micronutrient status within the European Commission funded project EURRECA (21) .
Data analysis
Polyphenols in urine were most often analyzed after enzymatic deconjugation of the polyphenol glucuronides and sulfate esters .100,000
with enzymes. For studies carried out without enzymatic hydrolysis of the conjugated forms, their urinary concentrations were converted into concentrations of aglycones, taking into account the respective molecular weight of the different conjugates and of the aglycone. All data on 24-h urinary recovery of polyphenols were converted to standard units (lmol/d) to facilitate comparisons across studies. When urine had been collected at several separate time intervals within 24 h, excretion rates for the different periods were used to estimate the 24-h excretion. When values were provided for periods longer than 24 h, excretion corresponding to the first 24 h was used. When urine had been collected as spot urine, data expressed as polyphenol concentration/creatinine concentration were converted to polyphenol excreted/d assuming a daily urinary creatinine excretion of 120 mg/dL, because it has been reported for US adults, although significant differences in excretion may be found according to sex, age, and other variables (22) . Data for polyphenol ingestion and/or excretion were corrected with control subject or baseline values, when available. Molar recovery for each polyphenol in each study was calculated as the amount ingested/amount excreted ·100, after conversion of the intake and excretion data to standard units. When the urinary polyphenol was known to originate from more than a single precursor present in the food or supplement ingested, only studies that reported the intake of all possible precursors were considered for recovery calculations. Recovery was then calculated considering the intake of all precursors (expressed in molar units) together.
Statistical analyses
Weighted mean molar recovery for each polyphenol was calculated according to the number of subjects in each included study. Recovery ranges indicate the minimum and the maximum recovery rates obtained in some of the included studies for a given polyphenol. Pearson's correlation coefficients were calculated to evaluate the relation between metabolite excretion and the intake of the corresponding precursor. The slope of the linear relation was determined according to the dose ingested.
RESULTS
A literature search of human intervention studies with polyphenols and polyphenol-rich foods resulted in nearly 2000 potential publications for inclusion ( Figure 1) . A review of titles and abstracts reduced the number of relevant publications, and, after screening the full text according to predefined criteria, 162 articles met the inclusion criteria for our systematic review. A complete list of these references is available as Supplementary Material (see "Supplemental data" in the online issue).
General characteristics of the studies
The number of studies included differs for each polyphenol class ( Figure 1 , Table 2 ). Isoflavones have been the most studied polyphenols to date, whereas few studies have been conducted on certain other classes, such as flavones, stilbenes, and ellagitannins. The number of subjects in each study was generally small (,10 subjects in .50% of the studies), and a significant fraction of the studies include .20 subjects only for the isoflavone and lignan classes. Most studies were acute, where a single polyphenol dose was ingested. Chronic studies remain poorly documented for most polyphenol subclasses, except for isoflavones and lignans.
Studies including control subjects were not common, and, for studies without a control arm, assessment of polyphenol concentrations at baseline was not systematically measured (Table  2) . In most studies, a washout period was followed before the intervention study to ensure that no polyphenols of interest would be present in urine at baseline.
Most studies focused on polyphenol-containing foods rather than on supplements or extracts, except for the flavones and stilbenes (Table 2) . A wide number of foods have been tested, including soy products as a source of isoflavones, orange and grapefruit juices as a source of flavanones, and olive and olive oil as a source of tyrosols. A large diversity of foods containing flavonols (broccoli, onion, tomato juice, red wine, tea, etc) or hydroxycinnamates (tea, beer, coffee, cereal bran, etc) were also tested. A variety of polyphenol supplements were fed, most often crude extracts obtained from polyphenol-rich foods such as tea or different berries, whereas only a few studies used pure polyphenols.
Urinary collection predominantly involved 24-h urine samples, and the amounts of metabolites excreted were generally reported per time intervals, urine volume, or amount of polyphenol ingested or normalized over creatinine when spot urine samples were collected (5% of the included studies). In the studies conducted to date, collection of urine beyond 24 h was rare, although such samples would be required for the assessment of microbial metabolites known to be excreted over 2-3 d, such as equol. In the large majority of the studies, polyphenol glucuronides and sulfate esters (the predominant forms in urine) were hydrolyzed with enzymes to their aglycones before analysis to facilitate their estimation.
Polyphenol metabolites in urine
One hundred fifty-eight metabolites (111 when the conjugated forms are not considered) originating from various classes of polyphenols have been described in the included studies (Table  2) . Most anthocyanins detected in urine are in the form of intact glycosides. A proportion of hydroxycinnamic acid esters, such as caffeoylquinic acids and rosmarinic acid, are also found in their intact form in urine. However, beyond these examples, most polyphenols quantified in urine are (sulfate and glucuronide conjugates of) aglycones formed by hydrolysis of the glycosides and esters in the intestine and some methylated metabolites formed from the aglycones in tissues and more particularly the liver.
Some microbial metabolites formed in the colon have also been found in urine (23) . These metabolites were ascribed a polyphenol precursor based on known pathways for their formation. Several metabolites are formed from isoflavones by the microbiota, including dihydrodaidzein, equol, and Odesmethylangolensin (O-DMA) for daidzein and dihydrogenistein from genistein (24) . Ellagitannins are metabolized by the microbiota into urolithin B (25) . Lignans are also metabolized by the colonic microbiota; secoisolariciresinol di-O-glucoside is transformed to enterodiol and further oxidized to enterolactone, whereas matairesinol is transformed to enterolactone (26) . Finally, the prenylchalcone isoxanthohumol is transformed by colonic fermentation to the flavanone 8-prenylnaringenin (24) .
Urinary recovery of polyphenols
Mean molar recovery and correlation with the dose of polyphenol ingested were evaluated for a selection of the 158 metabolites for which a precursor could be identified with no ambiguity (Table 3) . In general, a correspondence was observed between mean urinary recovery rates and the slope values of urinary excretion versus intake curves.
The highest percentage of dose recoveries was observed for isoflavones, and more particularly for daidzein (37%), glycitein (25%), and genistein (12%). Lower recoveries were observed for other isoflavones, such as formononetin (7.5%) and biochanin A (1.5%). The mean recovery of equol, the dihydrogenated metabolite of daidzein formed by the microbiota, was 4.7%. When non-equol producers were removed for the calculation, the mean equol recovery became 10% (data not shown). This high interindividual variability observed for the excretion of equol or O-DMA explains the poor correlations with intake observed for these 2 compounds. A similar recovery for dihydrogenistein, the dihydrogenated metabolite of genistein, was observed (10%).
We also examined the effect of the matrix ingested (foods or supplements) on urinary recovery of isoflavones; however, no significant differences were observed (data not shown). We also observed no differences in urinary excretion between acute and chronic isoflavone studies (data not shown).
Fewer data were available for polyphenols of other classes (Table  3) . Anthocyanins showed the lowest urinary recovery (systematically ,1%). Higher recoveries were observed for flavanols with values of '2% for (+)-catechin and (2)-epigallocatechin. The highest recovery for (2)-epicatechin (3.4%) was explained by one study in which a recovery .25% was observed after consumption of cocoa or chocolate (27) . Exclusion of this study resulted in a mean (2)-epicatechin recovery (from tea or cocoa powder) similar in magnitude (1.5%) to that of (+)-catechin and (2)-epigallocatechin. From the limited available studies, the nature of the food consumed (cocoa or chocolate, black tea or green tea) had no significant influence on catechin recovery (data not shown).
For flavonols, mean recoveries of 2.2% and 1.5% were obtained for kaempferol and quercetin, respectively. Most studies of flavonols were acute studies; 2 chronic studies (28, 29) showed recovery rates similar to those observed in single-dose trials (28, 29) . For flavanones, the urinary recovery was 5.5% (hesperetin) and 6.8% (naringenin). A recovery of 19% was observed for resveratrol.
High recovery yields were observed for enterodiol and enterolactone in intervention studies with either flaxseed or pure secoisolariciresinol (14-37%). Recovery yields of phenolic acids varied widely from 1.1% for rosmarinic acid to 12% for gallic acid. Recovery rates of phenolic alcohols in urine were calculated on the basis of all precursors ingested, hydroxytyrosol from hydroxytyrosol itself and ligstroside aglycone, and tyrosol from itself and oleuropein aglycone. However, because complete conversion of these precursors into tyrosol or hydroxytyrosol was assumed for this calculation and because this is known not to be the case (30), these recovery rates must be underestimated . The recovery yield of urolithin B after intake of various ellagitanninrich sources was 7.3%.
DISCUSSION
This study was the first attempt to collate and analyze in a systematic way urinary recovery data and correlations with the dose ingested in polyphenol intervention studies-information important for identifying potential biomarkers of polyphenol intake and status.
About 160 polyphenol metabolites have been described in urine in the included studies. Only some of them could be ascribed with certainty to known precursors (Table 3) . Several flavonoids, phenolic acids, stilbenes, lignans, tyrosols, coumarins, and chalcones were quantified, either as their intact glycosides (anthocyanins) and esters (5-caffeoylquinic acid, rosmarinic acid) or as their aglycones (Table 3) . In most studies, glucuronidated and sulfated derivatives resulting from the extensive conjugation of aglycones in the intestine and in the liver were enzymatically hydrolyzed before quantification.
The value of urinary polyphenol metabolites as biomarkers of intake depends on their specificity, sensitivity, and variability. A metabolite should first be specific for a particular polyphenol or a group of polyphenols. Some of the metabolites analyzed in urine can be misleading as biomarkers because they may arise either from ingestion of their food sources or from absorption and metabolism of other compounds. For example, ferulic acid or isorhamnetin are present in many foods and are also formed by methylation of caffeic acid or quercetin, respectively. Hippuric acid may originate from different polyphenols and also from other nonphenolic substances. They were therefore not included in the quantitative analysis of data carried out in the present work. (35) .20 ( (25) .20 (37) 1 Some studies dealt with polyphenols belonging to more than one of the classes. Some of the metabolites originated from different classes (see Table 3 ). 2 Tested in the same study.
TABLE 3
Relation between the dose of polyphenol ingested and its recovery in 24-h urine samples Biomarker sensitivity depends both on the concentration of the polyphenol metabolite in urine and on the sensitivity of the method used for its detection. Some polyphenols show very low recoveries in urine and this contributes to limit the sensitivity of the biomarker but also to increase measurement error. This is particularly true for anthocyanins for which recovery does not exceed 0.2%. For other polyphenols, recovery varies between 0.2% and 37%. The highest recoveries are observed here for enterolactone formed from secoisolariciresinol di-O-glucoside (37%) and for hydroxytyrosol formed from hydroxytyrosols in olive oil. Recovery of daidzein (37%) is more than 3-fold higher than that of genistein (12%), as previously reported (31) . For some polyphenols there has been enough data to study the effects of food matrix on urinary recovery. No difference in urinary recovery was observed for isoflavones originating from soyfoods or dietary supplement. Some contradictory results were previously published, which showed either no difference or a higher bioavailability of isoflavones from supplements (32, 33) . The amount of data in the present study may be insufficient to draw final conclusions.
Linear dose-response relations between the intake of polyphenols and the amount excreted in urine are generally observed in individual studies with anthocyanins (34, 35) , flavanols (36) , flavonols (28) , phenolic alcohols (37), hydroxycinnamates (38) , lignans (39, 40) , and stilbenes (41) , although saturation of recovery in urine has also been described in some studies of isoflavones or epigallocatechin (42) (43) (44) . Here, correlations were studied over a series of related clinical trials in which a given polyphenol was ingested, for a wide range of intakes and different sources for each polyphenol; r values .0.8 were obtained for daidzein, genistein, anthocyanins, and isoferulic acid. This indicates a certain robustness of the markers through the different trials, taking into account the variations in the study design, the kind of supplementation, the supplemented doses, and the analytic techniques used.
The strength of the correlation between intake and urinary excretion varied largely from one compound to the other. Weaker correlations were observed for microbial metabolites formed from isoflavones due to large interindividual variations in the host microbiota. Correlation coefficients are clearly lower for the 3 daidzein microbial metabolites (equol, O-desmethylangolensin, and dihydrodaidzein) when compared with daidzein (Table 3) . Similar results were obtained earlier in an observational study in which the same compounds were measured in urine samples and their levels compared with intake calculated from dietary record and isoflavone contents in foods (45) .
The present data show that some metabolites are more promising as biomarkers because of their high recovery in urine and good correlation with the dose ingested, notably 4 isoflavones: daidzein, genistein, formononetin, and glycitein. Enterolactone also appears to be a good biomarker for lignan consumption. However, all clinical trials of the lignans used secoisolariciresinol di-O-glycoside or flaxseed, its richest food source. Different results could be obtained with other foods containing much lower amount of lignans with different chemical structures. Last, hydroxytyrosol also appears to be a good marker for olive phenolic alcohols. Some polyphenols in urine are also well correlated with the dose but show a lower recovery yield. This is particularly true for anthocyanins. These compounds might be useful as biomarkers provided that sensitive analytic methods are developed for their estimation.
In contrast, some other metabolites show weaker correlations with dose, which suggest that they would be less reliable as markers of intake, ie, flavanones, catechins, quercetin, and the microbial metabolites of isoflavones such as dihydrodaidzein, equol, or O-desmethylangolensin. This does not exclude their possible use as biomarkers of intake, but a weaker accuracy should be expected. Last, there are a number of metabolites for which no correlation with the dose could be calculated because of the insufficient number of studies published thus far.
Altogether, this first systematic review on polyphenol urinary excretion showed that many metabolites estimated in urine respond to intake. Their concentrations in urine correlate with their intake, which suggests that all can be useful markers of intake. Their value as biomarkers will depend on the identification of all possible polyphenol precursors in foods, the level of correlation with the dose, their concentration in urine, and the existence of methods for their accurate estimation at current levels of exposure.
The data are limited by the lack of validation of these biomarkers in cohort studies. Good correlations were observed between their excretion in urine and the consumption of some of their major food sources (46) . This suggests that, at least in the population studied, these markers should be specific enough for the polyphenol considered. However, proper validation based on the intake of the polyphenol precursors and not only on the consumption of polyphenol-rich foods is still needed. The new Phenol-Explorer database on polyphenol content in foods now available makes such a validation possible (13) . Another limit of the present results is that correlations with intake were obtained in controlled intervention studies at intakes often higher than those most commonly encountered in free-living subjects. It will be important to estimate common concentration ranges in different cohorts, to validate analytic methods at these concentration ranges, and to check correlations with intake. More sensitive methods such as isotope-dilution mass spectrometry analysis or immunoassays might be needed to analyze metabolites at low concentrations. Once validated, these biomarkers of polyphenol intake should contribute to better assessment of associations with health and disease outcomes in population-based studies.
